scholarly journals Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients

2007 ◽  
Vol 10 (2) ◽  
pp. 194-201 ◽  
Author(s):  
M Usami ◽  
H Akaza ◽  
Y Arai ◽  
Y Hirano ◽  
S Kagawa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Luteinizing Hormone ◽  
Advanced Prostate Cancer ◽  
Japanese Patients ◽  
Multicenter Trial ◽  
Phase Iii ◽  
Double Blind ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone

Luteinizing-Hormone-Releasing Hormone Agonist plus Antiandrogen Regimens in the Treatment of Advanced Prostate Cancer

2002 ◽  
Vol 37 (5) ◽  
pp. 485-487
Author(s):  
J. Aubrey Waddell ◽  
Patrick M. Garman ◽  
Dominic A. Solimando
Keyword(s):  
Prostate Cancer ◽  
Luteinizing Hormone ◽  
Cancer Chemotherapy ◽  
Advanced Prostate Cancer ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Toxic Agents

The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.

Sign in / Sign up

Export Citation Format

Share Document